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OBJECTIVE: Chronic rejection remains a major cause of graft failure with indication for re-transplantation. The
incidence of chronic rejection remains high in the pediatric population. Although several risk factors have been
implicated in adults, the prognostic factors for the evolution and reversibility of chronic rejection in pediatric
liver transplantation are not known. Hence, the current study aimed to determine the factors involved in the
progression or reversibility of pediatric chronic rejection by evaluating a series of chronic rejection cases
following liver transplantation.
METHODS: Chronic rejection cases were identified by performing liver biopsies on patients based on clinical
suspicion. Treatment included maintaining high levels of tacrolimus and the introduction of mofetil
mycophenolate. The children were divided into 2 groups: those with favorable outcomes and those with
adverse outcomes. Multivariate analysis was performed to identify potential risk factors in these groups.
RESULTS: Among 537 children subjected to liver transplantation, chronic rejection occurred in 29 patients
(5.4%). In 10 patients (10/29, 34.5%), remission of chronic rejection was achieved with immunosuppression
(favorable outcomes group). In the remaining 19 patients (19/29, 65.5%), rejection could not be controlled
(adverse outcomes group) and resulted in re-transplantation (7 patients, 24.1%) or death (12 patients, 41.4%).
Statistical analysis showed that the presence of ductopenia was associated with worse outcomes (risk ratio=2.08,
p=0.01).
CONCLUSION: The presence of ductopenia is associated with poor prognosis in pediatric patients with chronic
graft rejection.
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’ INTRODUCTION
Despite advances in the field of liver transplantation,
chronic rejection (CR) remains a major cause of graft failure
and is a common indication for re-transplantation (1).
Although the incidence of CR in adults appears to be
decreasing and currently ranges from 2% to 5% (1), the
incidence of CR continues to range between 8% and 12% in
pediatric series (2–6). The best methods for the prevention
and treatment of CR remain elusive, and the CR recurrence
rate remains as high as 90% after re-transplantation (7).
CR is diagnosed based on histopathological findings. Loss of
bile ducts in more than 50% of portal tracts or the presence of
foam cell obliterative arteriopathy in the explanted rejected
liver are the main indicators of advanced CR. Loss of bile ducts
in less than 50% of portal tracts, biliary duct degeneration,
perisinusoidal fibrosis, and inflammation are considered
preliminary findings for CR after liver transplantation (8).
Previous reports have implicated several risk factors
for CR, including autoimmune disease in the recipient
(9-11), gender mismatch between donor and recipient
(12,13), recipient race (14), cytomegalovirus (CMV) infection
(15-17), recipient age (1), insufficient immunosuppression (1),
number and severity of acute rejection (AR) episodes, and
re-transplantation for CR (18). However, not all of the sug-
gested risk factors have been confirmed in subsequent
studies, and most studies have only included adult patients.
There may be qualitative differences in adult and pediatric
immune responses, and the risk factors for CR may differ
between pediatric and adult transplant recipients (19).
In the pediatric population, factors such as recipient
ethnicity, graft type, presence of autoimmune disease,
number of AR episodes, and occurrence of post-transplant
lymphoproliferative disease (PTLD) have been identified asDOI: 10.6061/clinics/2016(04)07
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predictors of CR (19). However, the prognostic factors for the
evolution and reversibility of CR in the pediatric liver
transplantation population are not known, as few reports
have focused on CR in pediatric patients. Thus, the aim of
the present study was to evaluate all cases of biopsy-proven
CR after liver transplantation in our center to identify factors
related to the progression or reversibility of CR.
’ METHODS
The study population included children undergoing
primary orthotopic liver transplantation at the Instituto da
Crianc¸a da Universidade de São Paulo between July 1989
and December 2013. Data were collected by retrospective
chart review and included age, gender and race of recipient;
type of graft; type of preservation solution used; presence of
inherent liver disease; duration between liver transplantation
and CR diagnosis; occurrence of AR episodes (number and
intensity); use of immunosuppressive therapy (drugs and
serial levels at the time of CR diagnosis); presence of CMV
and Epstein Barr virus (EBV) infection; occurrence of PTLD;
and presence of vascular and biliary complications. The
study protocol was previously approved by the Ethical
Committee of the University of São Paulo Medical School
(Surgery Division). Written informed consent was obtained
from the parents of all children enrolled in the study.
Prior to 2003, primary immunosuppression with cyclos-
porine and prednisone was used for all pediatric patients.
However, from 2003 onwards, cyclosporine was replaced
with tacrolimus. The diagnosis of CR was made according to
the recommendations of the International Panel of the Banff
Schema for Liver Allograft Rejection (8). Liver biopsies were
performed on the basis of clinical indication, which was most
often elevated liver chemistry. All patients underwent biopsy,
and the histopathological findings of all biopsies were
evaluated. The main pathological changes indicating CR
were vanishing bile duct syndrome and obliterative arterio-
pathy (Fig. 1). Early stages of CR were indicated by damage
to the inter-lobular bile duct, central perivenulitis, perisinu-
soidal fibrosis, and necrotic inflammation in the central lobule
and portal area. Pathological reports containing CR diagnoses
were retrieved from our liver pathology database within the
study period, and slides were reviewed by three experienced
transplantation pathologists (E.S.M, FL and R.Y.T.). Early and
late CR diagnoses were confirmed according to previously
published criteria (8), and special attention was paid to
exclude cases of relapsing autoimmune hepatitis or de novo
autoimmune hepatitis (20). Finally, in the last 10 cases, sera
was collected from the recipients and verified to contain
donor-specific anti-HLA antibodies.
All children with CR diagnosis were maintained on high
levels of tacrolimus (10-12) and were administered myco-
phenolate mofetil (MMF) if the tacrolimus level was already
high at the time of CR diagnosis. Reversal of histopatholo-
gical findings and improvement of liver chemistry tests were
considered favorable outcomes, whereas indication for re-
transplantation or patient death were considered adverse
outcomes. The patients were followed for periods ranging
from two years to 24 years.
Statistical Analysis
Data were subjected to descriptive and inferential statistical
analysis using Statistical Package for Social Sciences (SPSS) for
Windows, version 15.0. For descriptive procedures, we present
gross and relative measures (frequencies and percentages) and
measures for central tendency (mean) and variability (standard
deviation and confidence interval minimum and maximum).
The children were divided into two groups according to
disease evolution: a favorable outcome (FO) group and an
Figure 1 - Histopathological findings of liver biopsies. a. Central perivenulitis (hematoxylin-eosin); b. portal space without bile duct
(vanishing bile duct) (hematoxylin-eosin); c. lobular fibrosis (picrosirius); d. obliterative arteriopathy (hematoxylin-eosin).
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adverse outcome (AO) group. Multivariate analysis was
performed to identify potential risk factors for FO or AO.
’ RESULTS
Out of the 537 children who underwent liver transplanta-
tion at our institution, CR occurred in 29 patients (5.4%).
In 10 patients (10/29, 34.5%), remission of CR with
normalization of liver chemistry tests was achieved with
immunosuppression (FO group). In 19 patients (19/29,
65.5%), rejection could not be controlled, leading to re-
transplantation or death (AO group). The mean data for the
FO and AO groups are summarized in Table 1.
Primary immunosuppression was cyclosporine-based in
7 CR cases (24.1%) and tacrolimus-based in 22 (75.9%). The
mean tacrolimus serum level at the time of CR diagnosis was
9.7 ng/ml. Ductopenia was present in 11 of the CR cases
(37.9%), and foam cell arteriopathy was present in 2 cases
(6.9%). Centrilobular changes with fibrosis (68.9%) and
inflammation/phlebitis (58.6%) were frequently observed.
Most of the CR patients had a previous diagnosis of AR
(26 patients, 89.6%), and 17 of them (58.6%) presented two or
more episodes of AR. Fifteen CR patients (51.7%) had
previous episodes of severe AR. No patients had positive
donor-specific anti-HLA antibodies.
In 17 patients (58.6%), the diagnosis of CR was made
during the first post-transplant year, and in 7 patients
(24.1%), it was within the first 3 months. In terms of final
disease evolution, 10 patients (34.5%) survived after being
diagnosed with CR, 7 were re-transplanted (24.1%), and
12 (41.4%) patients died.
Multivariate analysis revealed no statistical correlation
between CR outcome and recipient age, gender mismatch
between donor and recipient, type of graft used, type of
preservation solution used, presence of liver disease, time
interval between liver transplantation and CR diagnosis,
presence of episodes of AR, immunosuppressive regimen at
CR diagnosis, presence of CMV and EBV infection, occur-
rence of PTLD, or presence of any vascular and biliary
complications. However, presence of ductopenia was asso-
ciated with worse outcomes (risk ratio=2.08, p=0.01).
Ten (90.9%) of the 11 patients with ductopenic CR were
submitted to re-transplantation or died. However, 7 out of
the 16 (43.3%) CR patients with no ductopenia presented
adverse outcomes.
Eight children underwent re-transplantation. Of these,
four did well with no CR relapse (50%). The causes of death
in the others were primary non-function (3 patients) and CR
relapse (1 patient). In the CR relapse case, the native liver
disease was non-syndromic ductopenia. Although high
levels of tacrolimus (410 ng/ml) were maintained post-
operatively, CR diagnosis was made less than 1 month after
re-transplantation.
’ DISCUSSION
Recent advances in surgical techniques and immunosup-
pression strategies, as well as the implementation of living-
related transplant programs and improvements in intensive
and postoperative care, have considerably increased pedia-
tric liver transplantation survival rates. CR is an important
cause of graft failure, and although the incidence of CR is
declining, it remains at 8% to 12% for pediatric liver allograft
recipients (2-6). The pathogenesis of CR remains uncertain.
The current study included a heterogeneous group of
patients who received cyclosporine or tacrolimus for primary
immunosuppression and underwent transplantation over a
period spanning 2.5 decades. Our aim was to identify factors
related to the progression or reversibility of CR. Although
several authors have reported an absence of CR under
tacrolimus-based immunosuppression (21,22), the incidence
of CR in our population was 5.4%, and most of these CR cases
were observed in children already on a tacrolimus regimen.
Interestingly, the median tacrolimus levels at the time of CR
diagnosis were deemed adequate (9). Furthermore, tacrolimus
level was not identified as a prognostic factor in our CR cases;
thus, we were not able to replicate the reported significant
biochemical improvement and normalized liver function after
optimization of baseline immunosuppression. Interestingly,
Barbier et al. compared the incidence of CR in patients under
high vs. low doses of calcineurin inhibitors and detected no
CR in liver graft recipients receiving immunosuppression with
low-dose calcineurin inhibitors (23).
Ma et al. investigated the clinical manifestations and
pathological features of CR as well the management of CR in
516 adult liver transplant patients (24). Although no typical
















Gender 5 F: 5 M 11 F: 8 M
Race 4 Caucasians 9 Caucasians






Underlying disease 4 BA, 2 AHF 11 BA: 2 AIH
1 AIH, 1 a1ATD 1 CC: 1 NSD
1 AS, 1 LSD 1 HCVC: 1 AS
1 PFIC: 1
a1ATD
Donor 7 DD 17 DD
3 LD 2 LD
Preservation solution 7 Belzer 13 Belzer
3 HTK 4 HTK
1 SPS1
1 Celsior
Ischemia time (mean ± SD) LD: 1.1±0.4 hrs LD:1.2±0.3 hrs
CD: 7.5±3.08 hrs CD: 7.17±1.64
hrs
Immunosuppressive regimen at CR
diagnosis
5 Tac + MMF 10 Tac + MMF
2 Tac 5 Tac
2 CyA 3 CyA
1 CyA + MMF 1 CyA + MMF
CMV infection 0 0
EBV infection 2 (20.0) 3 (15.7)
PTLD 1 (10.0) 2 (10.5)
Vascular complications 3 (30.0) 6 (31.6)
Biliary complications 4 (40.0) 7 (36.8)
(F: female; M: male; BA: biliary atresia; AHF: acute hepatic failure; AIH:
autoimmune hepatitis; a1ATD: alpha-1 antitrypsin deficiency; AS: Alagille
syndrome; LSD: lysosome storage disease; CC: choledochal cyst; NSD: non-
syndromic ductopenia; HCVC: hepatitis C virus cirrhosis; PFIC: progressive
familiar intrahepatic cholestasis; PTLD: post-transplant lymphoproliferative
disorder; LD: living donor: DD: deceased donor; Tac: tacrolimus; MMF:
mycophenolate mofetil; CyA: cyclosporine)
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clinical manifestation was found, their histological findings
were concordant with those reported here: vanishing bile
duct syndrome and obliterative arteriopathy at late stages,
and damage to the inter-lobular bile duct, necrotic inflam-
mation in the central lobule, and inflammatory cell infiltra-
tion in the portal area at early stages of CR. They reported an
incidence rate of 2.3% for CR, and most of their patients were
diagnosed at an early stage. Although they opted for more
aggressive management of early CR, including methylpred-
nisolone pulse, OKT3, and anti-thymocyte globulin treat-
ment, we had similar results and reversal indexes when
adjusting immunosuppressant doses and mofetil mycophe-
nolate introduction. All of their cases of late CR underwent
re-transplantation.
Although AR and CR are considered two different entities
with distinct histopathologic patterns, risk factors, and
immunological mechanisms, a great majority of our cases of
CR (89.6%) were preceded by one or more episodes of AR,
with episodes rated as severe in 51.7% of the cases. Prior
episodes of AR have already been described as a risk factor for
the development of CR in pediatric and adult liver transplan-
tation patients (19). Hence, this relationship may suggest
minor dysregulation or perturbation of the immune system or
an interaction between the graft and host in affected patients.
In this context, centrilobular necroinflammation seems to be a
common finding in both conditions. Neil et al. evaluated serial
biopsy specimens and failed allografts from 28 patients who
underwent re-transplantation for CR to identify histologic
features that were present during the early stages of CR. They
found that centrilobular necroinflammation associated with
portal tract features of AR were present when liver function
began to deteriorate. However, the prognosis of CR was not
influenced by previous episodes of AR (25). Finally, recent
investigations have implicated the importance of de novo
donor-specific antibodies in the sera of recipients with CR,
especially of HLA-class II type (26).
Despite recent advances in immunosuppression strategies
and the introduction of sirolimus therapy in combination
with cyclosporine as an effective treatment against CR after
liver transplantation (27), there are still limited options for
the treatment of this serious complication. In addition, the
overall survival without re-transplantation in our study
series was only 34.4%. Because the prevalence of CR is
relatively low in most centers and its immunological
mechanisms are not known, the identification of prognostic
factors in patients who develop CR will help predict the
evolution of the condition and inform decisions regarding
the need for and timing of re-transplantation.
In our study series, the majority of the factors studied (age,
gender, recipient race, gender and race of donor, type of
graft, type of preservation solution, native liver disease, time
between liver transplantation and CR diagnosis, episodes of
AR, immunosuppressive therapy, CMV and EBV infection,
occurrence of PTLD, vascular and biliary complications)
were not correlated with CR prognosis according to multi-
variate analysis. One possible reason for this finding may be
the relatively low number of cases. Collaborations with other
centers would increase study numbers and may reveal
potential statistical correlations and risk factors for the
development of CR in pediatric patients.
In conclusion, CR after pediatric liver transplantation is an
important cause of graft failure, with few effective treatment
options. The presence of ductopenia is associated with a poor
prognosis in CR cases.
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